Detalhe da pesquisa
1.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Eur J Haematol;
112(3): 379-391, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37899734
2.
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
J Infect Dis;
227(2): 206-210, 2023 01 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35921542
3.
Therapeutic plasma exchange for anticoagulant-refractory antiphospholipid syndrome with severe ischemic and necrotic skin lesions: A case series.
Transfus Apher Sci;
60(5): 103192, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34226147
4.
The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study.
Br J Haematol;
189(1): 171-181, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31730713
5.
Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.
Blood;
132(2): 223-231, 2018 07 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29773572
6.
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.
Haematologica;
104(5): 947-954, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30442723
7.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial.
Haematologica;
109(6): 1977-1983, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38268448
8.
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
Haematologica;
108(1): 240-244, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36073515
9.
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Haematologica;
102(1): 85-93, 2017 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27540137
10.
Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study).
Transfusion;
56(2): 311-20, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26442648
11.
Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.
J Immunol;
192(12): 5625-34, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24808368
12.
COVID-19-associated immune thrombocytopenia.
Br J Haematol;
190(2): e61-e64, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32420612
13.
Patchy hematopoiesis mimicking bone metastasis.
Blood;
132(15): 1626, 2018 10 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30309877
14.
Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold.
Transfusion;
60(4): 879-881, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32246478
15.
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Eur J Haematol;
93(5): 429-38, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24813620
16.
Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.
Mol Oncol;
2024 May 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38790134
17.
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
Blood Adv;
8(11): 2622-2634, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38507742
18.
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Blood;
118(14): 3765-76, 2011 Oct 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21753188
19.
Measuring Mitochondrial Oxygen Tension during Red Blood Cell Transfusion in Chronic Anemia Patients: A Pilot Study.
Biomedicines;
11(7)2023 Jun 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37509512
20.
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND.
Ther Adv Hematol;
13: 20406207221118429, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36105914